Sanofi releases Type 2 diabetes treatment in U.S.

Sanofi's Soliqua 100/33 product to treat adults with Type 2 diabetes is now available via prescription in U.S. pharmacies.
"We are encouraged by the potential of Soliqua 100/33, which has demonstrated superior HbA1c lowering vs. Lantus," Peter Guenter, executive vice president and head of the Global Diabetes & Cardiovascular Business Unit at Sanofi, said in a statement. "By offering Soliqua 100/33 – a product containing both a basal insulin and a GLP-1 therapy – at a competitive price while facilitating patient access, we believe we are providing value to patients and the health care system."
The wholesale cost of Soliqua 100/33 is $127 for a 300 Unit pen. This amounts to $19.90 per day when used at the average dose rate. Sanofi offers the product at a $0 co-pay rate for eligible U.S. patients with commercial insurance. It is in the process of securing coverage for Soliqua 100/33 on health plans across the nation.
"Health care professionals need a broad range of treatments to individualize a patient's diabetes care, particularly for the many adults living with diabetes who continue to face challenges in controlling their blood sugar levels even after treatment with basal insulin," Dr. George Grunberger, chairman of Grunberger Diabetes Institute, said. "This combination product provides a new option for many patients uncontrolled on basal insulin therapy or lixisenatide."